---
title: "Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279043374.md"
description: "In Shanghai on March 13, 2026, Unixell Biotech marked a major achievement when UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy, received clearance for Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA) on March 12."
datetime: "2026-03-13T12:07:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279043374.md)
  - [en](https://longbridge.com/en/news/279043374.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279043374.md)
---

# Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy

In Shanghai on March 13, 2026, Unixell Biotech marked a major achievement when UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy, received clearance for Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA) on March 12.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [UBX.US](https://longbridge.com/en/quote/UBX.US.md)
- [JYB.US](https://longbridge.com/en/quote/JYB.US.md)

## Related News & Research

- [Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft](https://longbridge.com/en/news/296352331.md)
- [ALLO: Allogeneic CAR T platform shows strong efficacy, safety, and broad market potential across key indications](https://longbridge.com/en/news/295718267.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)
- [Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline](https://longbridge.com/en/news/295945698.md)